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Abstract
Objective: The anatomic location of subsequent relapses in early multiple sclerosis (MS) appears to be predicted by the first
attack location. We sought to determine if genetic polymorphisms associated with MS susceptibility are associated with
attack location.
Methods: 17 genome-wide association study-identified MS susceptibility polymorphisms were genotyped in 503 white,
non-Hispanic patients seen within a year of MS onset. Their association with the CNS location of the first two MS attacks was
assessed in multivariate repeated measures analyses (generalized estimating equations with robust standard errors).
Results: The IL12A polymorphism was independently associated with increased odds of attacks involving the spinal cord
(OR=1.52, 95% CI 1.11, 2.07, p=0.009), as was the IRF8 polymorphism (OR=2.40, 95% CI [1.04, 5.50], p=0.040). The IL7R
polymorphism was associated with reduced odds of attacks involving the brainstem/cerebellum (OR=0.46, 95% CI 0.22,
0.97, p=0.041), as were the TNFRSF1A and IL12A polymorphisms. The CD6 polymorphism conferred reduced odds of optic
neuritis as an attack location (OR=0.69, 95% CI [0.49, 0.97], p=0.034). Several other genes showed trends for association
with attack location.
Conclusions: Some of the MS susceptibility genes may be associated with MS attack location. The IL12A polymorphism is of
particular interest given that interferon beta therapy appears to influence IL12 levels. These findings may lead to improved
understanding of MS pathogenesis and treatment.
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Introduction
While the anatomic location of multiple sclerosis (MS) attacks
differs from one person to the next, we have recently demonstrated
that an individual patient’s early attacks are likely to occur in the
same location within the central nervous system (CNS) [1]. In
other words, a person who has spinal cord involvement in the first
attack is likely to have involvement thereof during the second
attack, whereas a person with onset involving the optic nerve has
greater odds of experiencing optic neuritis during the second
attack. We hypothesized that genes known to be associated with
MS susceptibility may also determine various features of its
phenotype. In this investigation, we sought to determine if MS
PLOS ONE | www.plosone.org 1 October 2013 | Volume 8 | Issue 10 | e75565susceptibility genes are associated with the CNS location of early
MS attacks.
Methods
Ethics statement
This study was approved by the University of California, San
Francisco Committee on Human Research (CHR); each center
contributed data from patients enrolled in Institutional Review
Board-approved studies who had provided written informed
consent.
Subjects and sites
This is a retrospective study of white patients with clinically
isolated syndrome or relapsing-remitting MS. Race was restricted
to reduce genetic heterogeneity. Subjects at five MS centers
(UCSF, San Francisco, USA; MS Unit, Marseille, France; Centre
Hospitalier de L’Universite ´ de Montreal, Montreal, Canada;
University of Navarra, Spain; Hospital Puerta de Hierro
Neuroimmunology Unit, Madrid, Spain); and from two clinical
trials (Controlled High Risk Avonex Multiple Sclerosis Prevention
Study in Ongoing Neurologic Surveillance [CHAMPIONS] and
Optic Neuritis Treatment Trial [ONTT])[2,3] who were seen
within a year of their first attack and who had brain magnetic
resonance imaging (MRI) within six months of symptom onset
were included. At UCSF, three different cohorts were evaluated.
The first was the UCSF MS Center database, in which data for all
patients (children and adults) seen in the first year of MS onset are
entered. Routine clinic visits for UCSF patients typically take place
every 6 months. Subjects from two trials (the atorvastatin and
riluzole trials) were also included [4,5]. Atorvastatin participants
were seen within 90 days of onset and were evaluated monthly for
three months and then quarterly (total duration of follow-up was
18 months). For the riluzole study (which was incomplete when the
data were frozen for this analysis), patients were enrolled in the
first year of MS onset; they were evaluated monthly for six months
and then quarterly for two to three years. In all three cohorts,
additional visits were scheduled for suspected relapses. At Aix
Marseille Universite ´, records of patients seen within six months of
disease onset who participated in a prospective longitudinal study
of MS that began in 2000 were retrieved from the EDMUS
database [6]. In this cohort, patients had clinic visits and MRIs
every 3 months for a year, then every 6 months for 3 years, and
annually thereafter. Patients at L’Universite ´ de Montreal, Canada
were offered participation in an observational study from
September, 2007 until March, 2009. Visits occurred at least once
a year but were more frequent if the disease was active. Patients
evaluated at the University of Navarra, Spain were enrolled at the
time of MS onset in a prospective MS biomarker study (using the
EDMUS database) that began in 2001 and were clinically
evaluated every 3 to 6 months thereafter [7]. At the Universitario
Puerta de Hierro, CIS patients evaluated within a year of
symptom onset had a neurologic examination at three months
and were followed biannually thereafter, with additional visits for
suspected relapses. The Optic Neuritis Treatment Trial (ONTT)
enrolled participants within 8 days of optic neuritis onset [8].
Because some had had prior symptoms, only those without
symptoms consistent with a previous MS/CIS attack were
included. The participants were re-evaluated on days 4, 15, and
30, weeks 7, 13, and 19, months 6 and 12, and then annually [3].
The Controlled High Risk Avonex Multiple Sclerosis Prevention
Study in Ongoing Neurologic Surveillance (CHAMPIONS) study
was an extension study (open-label) of Controlled High Risk
Subjects Avonex Multiple Sclerosis Prevention Study (CHAMPS)
[2,9]. CHAMPS enrolled subjects with a first attack if they were
evaluated within 27 days of the onset of the neurologic symptoms
and had an abnormal brain MRI (at least 2 lesions consistent with
MS that had no corresponding clinical symptoms). Participants
were randomized to intramuscular interferon beta-1a (weekly)
versus placebo. CHAMPIONS enrolled CHAMPS subjects who
gave consent into an open-label follow-up study. Subjects were
evaluated biannually in both studies and within a week
(CHAMPS) or two weeks (CHAMPIONS) of the onset of new
symptoms concerning for relapse.
Outcomes
Relapses, by definition, were new or recurring neurological
symptoms that were referable to the CNS and lasted for at least
48 hours after a period of at least 30 days since the prior attack in
the absence of fever or known infection. Transient recurrence of
neurologic symptoms that began in the context of infection or
fever was considered a pseudoexacerbation and was excluded.
Based on clinical history and examination, each patient’s relapses
were coded as occurring in the spinal cord, brainstem/cerebellum,
optic nerve, or cerebrum.
Predictors
The predictors of interest were 16 non-HLA genetic polymor-
phisms that had been validated for MS susceptibility as of 2010
(Table S1 in File S1) [10–20]. In the UCSF laboratory of Dr. Jorge
Oksenberg, TaqMan SNP genotyping assays were used for
genotyping (Applied Biosystems Inc., Foster City, CA, USA).
Each PCR reaction contained 10 ng of DNA, 1 x TaqMan
Genotyping Master Mix, and 1 x SNP assay (both from Applied
Biosystems, Inc.). Amplification was performed with an ABI 97000
GeneAmp PCR system (Applied Biosystems, Inc.). The PCR
program used was: 95u Celsius for 10 minutes followed by 50
cycles of 95u Celsius for 15 seconds and then 62u Celsius for one
minute. The plates were read with an ABI prism 7900HT
Sequence Detection System (with SDS 2. software; Applied
Biosystems, Inc.). DRB1 genotyping was performed using a PCR
locus-specific amplification, as previously described [19].
Statistics
Summaries are given as percentages for categorical variables
and as mean 6 standard deviation (SD) or median (interquartile
range) for continuous variables. For each of the four attack
locations, a dichotomous outcome variable was defined as any
involvement of the region versus no involvement. The presence of
at least one copy of each risk allele versus no copies of the allele
was assessed for its association with attacks involving each CNS
location using generalized estimating equations with robust
standard errors. This repeated measures approach was used to
account for within-individual correlations and to take into account
the location data from both the first and second attack in the same
model. All of the non-HLA susceptibility genes, as well as HLA-
DRB1 status, were included in the models so that the independent
effect of each gene could be determined. We also looked for
interactions (with strong evidence defined by p value for
interaction term ,0.1) between HLA-DRB1 and EVI5 and HRA-
DRB1 and CD226, because such interactions have been identified
in the MS susceptibility studies [15,17].
Results
Patient and attack characteristics
We identified 503 patients (359 [71%] were women) seen within
one year of MS onset (n=199 from UCSF; n=43 from Marseille;
MS Susceptibility Genes and Relapse Location
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Madrid; n=68 from CHAMPIONS; n=84 from ONTT). The
average age of onset was 3369 years; median disease duration was
46 days (interquartile range: 1, 351). Nearly all (459; 91%) patients
had an abnormal brain MRI at baseline. On average, there were
7.5 (65.2) years of follow-up. During the first attack, the following
number of subjects had involvement of each location: spinal cord
(207 [41%]); brainstem/cerebellum (126 [25%]); optic nerve (198
[39%]); cerebrum (12 [2%]). First attack location could not be
definitively ascertained for 3 individuals. Of the 349 patients who
had a second attack, a definite location could be ascribed for 302
attacks; of these, 171 (58%) had spinal cord involvement, 74 (25%)
had brainstem/cerebellar involvement, 61 (21%) had optic nerve
involvement, and 7 (2%) had cerebral involvement. The location
of 45 of the 58 second attacks experienced by ONTT subjects
could not be ascertained; second attack location could not be
definitively ascertained for 2 additional individuals. Because some
patients experienced attacks in more than one CNS location (and
because attack location was missing for other participants), the
percentages do not add up to 100% (and the numbers don’t add
up to the total number of attacks). Because so few subjects had
cerebral attacks, we were unable to assess it as an outcome.
Disease-modifying therapy (DMT) was started in 345 patients
(69%) at some point in the follow-up period, but only 134 (27%)
had received treatment for the 90 days immediately preceding the
second attack or the end of follow-up (if no second attack
occurred).
Details of genotype frequencies are provided in Table S1 in File
S1. One gene (IRF8) in one patient failed genotyping. There were
no subjects without at least one copy of the TYK2 G allele, so for
this gene we assessed if two G alleles versus one was associated
with attack location. No subject had more than one copy of the
TNFRSF1A T allele; as such, we evaluated if having one versus no
copies of the T allele was associated with attack location.
Approximately half (n=244; 49%) of the subjects had at least
one copy of HLA-DRB1*1501 (the risk allele).
Predictors of spinal cord involvement
The multivariate associations of the susceptibility polymor-
phisms with spinal cord involvement during the first two attacks
are presented in Tableo ˆ 1. The IL12A polymorphism was
associated with greater odds of spinal cord attacks (OR 1.52,
95% CI [1.11, 2.07], p=0.009). IRF8 was also associated with
greater odds of spinal cord involvement (OR=2.40, 95% CI
[1.04, 5.50], p=0.040). There were trends for associations of
TNFRSF1A and TMEM39A with increased odds of spinal cord
involvement and of IL2RA and GPC5 with reduced odds
thereof. There was no strong evidence for interaction of HLA-
DRB1 with EVI5 (p value for interaction term=0.28) or with
CD226a (p value for interaction term=0.66). The estimates of
association were similar in the univariate models (Table S2 in
File S1).
Predictors of brainstem/cerebellum involvement
In the multivariate model, the IL7R polymorphism was
associated with lower odds of brainstem/cerebellar involvement
(OR 0.46, 95% CI [0.22, 0.97], p=0.041). The IL12A (OR 0.72,
95% CI [0.51, 1.02], p=0.068) and TNFRSF1A (OR 0.55, 95%
CI [0.30, 1.02], p=0.056) polymorphisms tended to be associated
with reduced odds of involvement of the brainstem/cerebellum,
while the opposite was true of the MPHOSPH9 polymorphism,
although the confidence intervals included 1.0. Again, there was
no strong evidence for interaction of HLA-DRB1 with EVI5 (p
value for interaction term=0.89) or with CD226a (p value for
interaction term=0.17). The univariate models had similar results
(Table S2 in File S1).
Table 1. Predictors of attack location (multivariate models).
Spinal cord Brainstem/cerebellum Optic nerve
IL12A 1.52 (1.11, 2.07), p=0.009 0.72 (0.51, 1.02), p=0.068 0.85 (0.60, 1.20), p=0.36
TMEM39A 2.10 (0.83, 5.33), p=0.12 3.11 (0.39, 24.81), p=0.29 0.21 (0.04, 1.17), p=0.075
IL7R 1.29 (0.61, 2.70), p=0.51 0.46 (0.22, 0.97), p=0.041 1.09 (0.53, 2.24), p=0.82
IL2RA 0.59 (0.29, 1.20), p=0.15 1.30 (0.58, 2.89), p=0.52 0.88 (0.38, 2.02), p=0.76
CD6 1.16 (0.85, 1.58), p=0.36 1.15 (0.82, 1.61), p=0.41 0.69 (0.49, 0.97), p=0.034
MPHOSPH9 0.95 (0.69, 1.30), p=0.75 1.26 (0.90, 1.76), p=0.18 0.77 (0.55, 1.09), p=0.14
TNFRSF1A 1.50 (0.91, 2.47), p=0.11 0.55 (0.30, 1.02), p=0.056 0.91 (0.51, 1.62), p=0.75
IRF8 2.40 (1.04, 5.50), p=0.040 0.70 (0.33, 1.51), p=0.36 0.76 (0.31, 1.86), p=0.55
GPC5 0.73 (0.53, 1.00), p=0.051 1.02 (0.71, 1.46), p=0.92 1.24 (0.88, 1.76), p=0.22
HLA-DRB1 1.02 (0.75, 1.39), p=0.88 1.03 (0.73, 1.45), p=0.85 1.06 (0.75, 1.49), p=0.75
CD58 0.54 (0.16, 1.79), p=0.32 0.79 (0.25, 2.49), p=0.69 1.33 (0.38, 4.64), p=0.66
RGS1 1.44 (0.53, 3.94), p=0.47 0.51 (0.16, 1.66), p=0.27 0.84 (0.28, 2.51), p=0.75
EVI5 0.96 (0.69, 1.34), p=0.80 1.19 (0.82, 1.73), p=0.36 0.80 (0.56, 1.15), p=0.23
KIF21B 1.46 (0.76, 2.78), p=0.25 1.03 (0.51, 2.10), p=0.93 0.86 (0.44, 1.68), p=0.65
CLEC16A 0.99 (0.58, 1.71), p=0.98 0.79 (0.47, 1.32), p=0.36 1.19 (0.68, 2.10), p=0.54
CD226a 1.04 (0.73, 1.47), p=0.83 0.98 (0.67, 1.41), p=0.89 1.11 (0.76, 1.62), p=0.58
TYK2 1.45 (0.61, 3.42), p=0.40 0.96 (0.38, 2.39), p=0.92 0.67 (0.30, 1.47), p=0.32
Results presented as odds ratios (95% confidence intervals), p values. The analyses take into account first and second attack locations. Of the entire cohort (n=503), 349
had a second attack. Attack location could not be resolved for 3 initial attacks and 47 second attacks.
doi:10.1371/journal.pone.0075565.t001
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The CD6 polymorphism was associated with reduced odds of
optic neuritis during the first two attacks (OR=0.69, 95% CI
[0.49, 0.97], p=0.034). There were trends for associations of the
TMEM39A and MPHOSPH9 polymorphisms with reduced odds of
optic neuritis as well. There was no strong evidence for interaction
of HLA-DRB1 with EVI5 (p value for interaction term=0.48) or
with CD226a (p value for interaction term=0.95). The results were
not meaningfully different in the univariate models (Table S2 in
File S1).
Discussion
In this study, we have identified, among genetic polymorphisms
known to increase the risk of MS, several that also may play a role
in the CNS location of early MS attacks. While the confidence
intervals are wide, such that the associations should not be over-
interpreted, the results are intriguing from a scientific standpoint.
Both the IL12A and the IRF8 polymorphisms were associated with
spinal cord involvement. Secreted by dendritic cells and mono-
cytes, IL12 stimulates IFNc and suppresses TH2 cells [20]. The
initiation of treatment with an approved MS disease-modifying
therapy, interferon beta-1a, leads to increased expression of IL12
[21]. In light of these data, that the IL12A polymorphism is
associated with increased spinal cord involvement is of interest
given our previous work showing that patients treated with
interferon beta were more likely to experience spinal cord
involvement during attacks, an association that was independent
of having had prior attacks involving the spinal cord [1,22]. In
contrast, subgroup analyses of the CHAMPS study showed that
treatment with interferon seemed to confer the strongest protective
effect against conversion to MS after the first attack in those whose
first attack localized to the spinal cord [23]. The exact role that
IL12 plays in the frequency and location of MS attacks, as well as
the functional consequences of the polymorphism known to be
associated with MS risk, thus demands further investigation.
The connection between polymorphisms in the other genes
identified here and altered MS attack location is less clear. IRF8
has been associated with regulating innate immunity, with B cell
development, and with the differentiation of CD8+ T cells [24].
IL7 is important to many immune functions, including T cell
differentiation and maintenance, and the IL7R polymorphism
confers a functional change; specifically, it leads to an increase in
the soluble (versus membrane-bound) form of the IL7R a chain
[25]. Finally, the CD6 gene product is involved in continuing the
activation of T cells; CD4+ T cell proliferation is reduced in
healthy people with two copies of the risk allele [26]. Alternatively,
the polymorphisms may influence MS attack location based on
local molecular properties in these regions, such as differential
expression of adhesion blood-brain barrier molecules, similar to
the finding that aquaporin-4 protein is located in the spinal cord,
hypothalamus, and optic nerve, driving the involvement of these
regions in neuromyelitis optica. The genes could also have roles
that vary depending on CNS location.
Limitations of the study include that the results may not be
generalizable to non-white patients with MS. That some ONTT
patients were missing detailed data regarding second attack
locations may have introduced some bias. Also, in some of the
models, the 95% CIs included 1.0 even when a convincing
direction of association emerged. Because genotyping for this study
occurred prior to the publication of the 2011 MS genome-wide
association study [27], we were unable to evaluate some of the
susceptibility SNPs identified in that study for their association
with relapse location. Finally, although the factors all have some a
priori plausibility for influencing the phenotype of MS due to their
known influence on susceptibility, it is possible that these findings
are still due to chance given the number of analyses. Because this
was a preliminary study in which the goal was to explore, rather
than definitively ascertain, the associations between the SNPs and
relapse location, we were more interested in evaluating the
magnitudes and directions of the effects seen rather than only
focusing on the p-values and performing adjustments for multiple
comparisons. Our results thus need replication in a large,
independent dataset, ideally including the more recently-identified
MS risk alleles at the time such a study is conducted [27].
The location of early MS attacks within the CNS does not
appear to be random. Here, we have identified that some of the
genes important to MS susceptibility also influence which
anatomic structures are affected. While the interplay between
these genes and other as yet unknown factors important to attack
location is not completely clear, the results presented here add to
the growing support for utilizing genetics to predict disease
outcomes in MS and to tailor therapies, based on those
predictions, to each individual with the disease.
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